Mangalam Drugs & Organics Limited (BOM:532637)
India · Delayed Price · Currency is INR 51.92
+2.47 (4.99%)
At close: Jan 20, 2026
Mangalam Drugs & Organics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 2,376 | 3,176 | 3,674 | 3,702 | 4,509 | 3,800 | Upgrade |
| 2,376 | 3,176 | 3,674 | 3,702 | 4,509 | 3,800 | Upgrade | |
Revenue Growth (YoY) | -31.47% | -13.55% | -0.77% | -17.89% | 18.66% | 34.58% | Upgrade |
Cost of Revenue | 1,479 | 1,702 | 2,472 | 2,536 | 3,101 | 2,558 | Upgrade |
Gross Profit | 897.36 | 1,474 | 1,201 | 1,166 | 1,408 | 1,242 | Upgrade |
Selling, General & Admin | 388.09 | 421.82 | 403.56 | 359.68 | 396.96 | 304.93 | Upgrade |
Other Operating Expenses | 491.71 | 690.5 | 623.42 | 550.29 | 520.32 | 400.29 | Upgrade |
Operating Expenses | 1,062 | 1,278 | 1,173 | 1,020 | 1,020 | 796.97 | Upgrade |
Operating Income | -165.14 | 195.61 | 27.98 | 146.34 | 387.99 | 444.8 | Upgrade |
Interest Expense | -134.04 | -111.8 | -104.09 | -89.21 | -72.02 | -63.21 | Upgrade |
Interest & Investment Income | 0.58 | 0.58 | 0.96 | 2.98 | 0.01 | 6.22 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | - | 37.43 | Upgrade |
Other Non Operating Income (Expenses) | -38.81 | -37.27 | -35.06 | -37.94 | -39.59 | -30.05 | Upgrade |
EBT Excluding Unusual Items | -337.4 | 47.12 | -110.21 | 22.17 | 276.37 | 395.19 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.89 | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.74 | 0.74 | -0.52 | -0.03 | - | - | Upgrade |
Pretax Income | -336.66 | 47.86 | -110.73 | 22.14 | 277.33 | 395.19 | Upgrade |
Income Tax Expense | -27.45 | -19.35 | -20.02 | 9.44 | 80.76 | 115.48 | Upgrade |
Net Income | -309.21 | 67.21 | -90.72 | 12.7 | 196.58 | 279.71 | Upgrade |
Net Income to Common | -309.21 | 67.21 | -90.72 | 12.7 | 196.58 | 279.71 | Upgrade |
Net Income Growth | - | - | - | -93.54% | -29.72% | 238.94% | Upgrade |
Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade |
Shares Change (YoY) | 0.08% | - | - | - | - | - | Upgrade |
EPS (Basic) | -19.53 | 4.25 | -5.73 | 0.80 | 12.42 | 17.67 | Upgrade |
EPS (Diluted) | -19.53 | 4.25 | -5.73 | 0.80 | 12.42 | 17.67 | Upgrade |
EPS Growth | - | - | - | -93.56% | -29.72% | 239.16% | Upgrade |
Free Cash Flow | - | 223.93 | -79.2 | 116.09 | -19.6 | -38.86 | Upgrade |
Free Cash Flow Per Share | - | 14.15 | -5.00 | 7.33 | -1.24 | -2.46 | Upgrade |
Gross Margin | 37.76% | 46.41% | 32.71% | 31.50% | 31.22% | 32.68% | Upgrade |
Operating Margin | -6.95% | 6.16% | 0.76% | 3.95% | 8.61% | 11.71% | Upgrade |
Profit Margin | -13.01% | 2.12% | -2.47% | 0.34% | 4.36% | 7.36% | Upgrade |
Free Cash Flow Margin | - | 7.05% | -2.16% | 3.14% | -0.43% | -1.02% | Upgrade |
EBITDA | 33.77 | 330.21 | 76.84 | 241.08 | 473.58 | 521.14 | Upgrade |
EBITDA Margin | 1.42% | 10.40% | 2.09% | 6.51% | 10.50% | 13.71% | Upgrade |
D&A For EBITDA | 198.91 | 134.6 | 48.86 | 94.74 | 85.6 | 76.34 | Upgrade |
EBIT | -165.14 | 195.61 | 27.98 | 146.34 | 387.99 | 444.8 | Upgrade |
EBIT Margin | -6.95% | 6.16% | 0.76% | 3.95% | 8.61% | 11.71% | Upgrade |
Effective Tax Rate | - | - | - | 42.63% | 29.12% | 29.22% | Upgrade |
Revenue as Reported | 2,389 | 3,187 | 3,687 | 3,727 | 4,512 | 3,847 | Upgrade |
Advertising Expenses | - | 15.95 | 12.85 | 13.56 | 24.44 | 6.14 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.